Begin main content

Drugs for Type 2 Diabetes: Second- and Third-Line Therapy Review Update

Published on: August 10, 2016
Project Number: TR0012 and TR0013
Product Line: Therapeutic Review
Result type: Report

CADTH is undertaking a project to assess the clinical and cost-effectiveness of new drugs for the treatment of patients with type 2 diabetes. These new drugs are in three classes: dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogues, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. As part of this project, recommendations from the CADTH Canadian Drug Expert Committee (CDEC) will be developed.

This project is an update to two large projects on pharmacotherapy for type 2 diabetes completed by CADTH in the past: an evaluation of second- and third-line therapies for type 2 diabetes originally published in 2010 and an update to this evaluation in 2013.

The following components have been completed:

  • a science report (clinical and economic evaluations)
  • a recommendations report on second-line therapies.

Reports related to third-line therapies are in development.